Faeth Therapeutics
FTH
26 hedge funds and large institutions have $4.71M invested in Faeth Therapeutics in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
20% more capital invested
Capital invested by funds: $3.92M → $4.71M (+$791K)
4% more funds holding
Funds holding: 25 → 26 (+1)
1.57% more ownership
Funds ownership: 8.56% → 10.13% (+1.6%)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
+$571K |
| 2 |
Morgan Stanley
New York
|
+$190K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$130K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$61.2K |
| 5 |
Millennium Management
New York
|
+$4.38K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$70.2K |
| 2 |
WSL
Western Standard LLC
Los Angeles,
California
|
-$68.7K |
| 3 |
VF
Virtu Financial
New York
|
-$39K |
| 4 |
E
Ergoteles
New York
|
-$27.9K |
| 5 |
Two Sigma Investments
New York
|
-$23.4K |
FTH Hedge Fund Activity: Q1 2023 in Review
26 of the 6,284 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q1 2023, worth a combined $4.71M — up 20% from $3.92M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new FTH positions and 3 closed out — a net gain of 1 holder — while 6 added to existing stakes and 7 trimmed.
The largest buyer was Newtyn Management, adding an estimated $571K. The largest seller was Renaissance Technologies, cutting an estimated $70.2K.
- 26 institutional investors held Faeth Therapeutics (FTH) as of Q1 2023, up from 25 in Q4 2022.
- Funds reported $4.71M of Faeth Therapeutics stock for Q1 2023, up 20% quarter-over-quarter.
- 4 funds opened new Faeth Therapeutics positions in Q1 2023 and 3 closed out, a net change of +1 holder.
- The largest Faeth Therapeutics buyer in Q1 2023 was Newtyn Management, an estimated $571K added.
- The largest Faeth Therapeutics seller in Q1 2023 was Renaissance Technologies, an estimated $70.2K sold.
Based on aggregated 13F filings for Q1 2023.